In the BioHarmony Drug Report Database
Encorafenib
Braftovi (encorafenib) is a small molecule pharmaceutical. Encorafenib was first approved as Braftovi on 2018-06-27. It is used to treat melanoma in the USA. It has been approved in Europe to treat colorectal neoplasms and melanoma. Braftovi’s patents are valid until 2033-08-05 (FDA).
Trade Name
|
Braftovi |
|---|---|
Common Name
|
encorafenib |
ChEMBL ID
|
CHEMBL3301612 |
Indication
|
colorectal neoplasms, melanoma |
Drug Class
|
Raf kinase inhibitors |
Image (chem structure or protein)